
Relmada Therapeutics RLMD
$ 7.03
-0.21%
Quarterly report 2026-Q1
added 05-12-2026
Relmada Therapeutics Depreciation & Amortization 2011-2026 | RLMD
Annual Depreciation & Amortization Relmada Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.26 K | 3.75 K | 4.36 K | 2.63 K | 85.3 K | 54.8 K | 9.26 K | - | 373 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 85.3 K | 373 | 20.2 K |
Quarterly Depreciation & Amortization Relmada Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26 K | 1.26 K | 806 | - | 2.93 K | 2.08 K | 1.05 K | - | 1.1 K | 2.16 K | 1.08 K | - | 1.4 K | 2.71 K | 1.4 K | - | 548 | 1.13 K | 548 | - | 20.2 K | 43.7 K | 20.2 K | - | 2.95 K | 5.91 K | 2.95 K | - | 3.59 K | 3.5 K | 3.59 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.7 K | 548 | 5.33 K |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals
CPIX
|
4.15 M | $ 6.29 | 7.07 % | $ 93.4 M | ||
|
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
84 K | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
14.2 M | $ 2.75 | 0.18 % | $ 1.05 B | ||
|
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
1.32 M | $ 33.59 | 1.79 % | $ 1.23 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | ||
|
Pacira BioSciences
PCRX
|
78.8 M | $ 24.14 | 3.38 % | $ 1.12 B | ||
|
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
1.21 B | $ 5.43 | -0.82 % | $ 2.01 B | ||
|
Organogenesis Holdings
ORGO
|
15.3 M | $ 2.63 | -1.32 % | $ 333 M | ||
|
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.05 | 1.1 % | $ 113 M | ||
|
Solid Biosciences
SLDB
|
1.64 M | $ 6.8 | 2.64 % | $ 595 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 1.08 | -2.27 % | $ 1.34 M | ||
|
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
35.7 M | $ 5.42 | 2.46 % | $ 3.35 B | ||
|
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | ||
|
Evolus
EOLS
|
7.51 M | $ 6.2 | 1.72 % | $ 400 M | ||
|
Emergent BioSolutions
EBS
|
95.8 M | $ 9.06 | 7.22 % | $ 485 M | ||
|
Veru
VERU
|
152 K | $ 2.3 | -2.17 % | $ 33.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
3.04 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
30 M | $ 23.45 | 0.04 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
361 K | $ 0.74 | -2.6 % | $ 2.98 M | ||
|
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | ||
|
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
580 K | $ 0.7 | -4.33 % | $ 35 M | ||
|
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
2.8 B | $ 16.29 | -2.19 % | $ 19 B | ||
|
Zomedica Corp.
ZOM
|
2.06 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
2.19 M | $ 0.75 | -5.4 % | $ 27 M | ||
|
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
1.5 M | $ 0.76 | 0.05 % | $ 3.26 M | ||
|
TherapeuticsMD
TXMD
|
384 K | $ 2.1 | -1.16 % | $ 24.3 M |